Cipla Ltd received USFDA approval on April 10, 2025, for its injectable cancer treatment, Protein-bound Paclitaxel, expected to launch in H1 FY 2025-26.
AI Assistant
Cipla Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.